SmartNuclide Biotech

SmartNuclide Biotech is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative radiopharmaceuticals and biologics for oncology and nuclear medicine. Founded in 2015 and headquartered in Suzhou, China, the company leverages its proprietary single-domain antibody (nanobody) and radionuclide conjugation platforms (such as the SRC platform) to develop precise diagnostic imaging agents and targeted radioligand therapies. Its lead product, ZhiShuJia (SNA001), a recombinant human thyroid-stimulating hormone (rhTSH), was approved in China in April 2024 for use in thyroid cancer patients undergoing radioactive iodine therapy. SmartNuclide's robust pipeline also includes several clinical-stage radiopharmaceutical candidates targeting PD-L1, CD8, HER2, Claudin 18.2, and GPA33 for various solid tumors and gastrointestinal cancers.